Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28246635 | 0.80 | FFAR1 (0.49) | FFAR1FFAR4ALDH1A1FABP7FABP3 | |
| SCHEMBL14587026 | 0.78 | ALDH1A1 (0.40) | NCEH1MAOAMAOBRAB9AKCNH2 | |
| SCHEMBL24018751 | 0.75 | HTR2A (0.49) | MAOAMAOBRAB9AKCNH2ALDH1A1 | |
| SCHEMBL26508862 | 0.74 | RAB9A (0.46) | NCEH1MAOAMAOBRAB9AHTT | |
| SCHEMBL24499264 | 0.74 | NCEH1 (0.43) | NCEH1MAOAMAOBRAB9AKCNH2 | |
| SCHEMBL551293 | 0.73 | AR (0.53) | ALDH1A1 | |
| SCHEMBL2525745 | 0.73 | ALDH1A1 (0.43) | NCEH1MAOAMAOBRAB9AKCNH2 | |
| Hydrochloric Acid SCHEMBL2525743 | 0.72 | ALDH1A1 (0.45) | NCEH1MAOAMAOBRAB9AKCNH2 | |
| SCHEMBL7342249 | 0.71 | ADRB1 (0.47) | FFAR1FFAR4RAB9AHTTALDH1A1 | |
| SCHEMBL25235502 | 0.71 | FFAR1 (0.64) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7491819-B1 | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491819-B1 | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1749011-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | NAIDU B N | 2006-12-07 | — | — | US | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | FFAR1 4457/4885FFAR4 4784/4885NCEH1 2050/4885 |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | FFAR1 4457/4885FFAR4 4784/4885NCEH1 2050/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | FFAR1 4457/4885FFAR4 4784/4885NCEH1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.